Pulse Biosciences (PLSE) investor relations material

Strategic focus and technology overview

• Exclusive focus on developing proprietary nanosecond pulsed field ablation (nsPFA) energy for electrophysiology and other ablation targets, supported by a robust intellectual property portfolio.

• Over a decade of investment has produced extensive pre-clinical and clinical evidence, with a strong commitment to rigorous data generation and clinical impact.

• Leadership team strengthened with recent additions of experienced executives and a full-time Chief Medical Officer to accelerate execution and clinical programs.

• Board of directors includes seasoned med tech operators and investors, providing governance and strategic guidance.

Financial position and operational outlook

• Ended 2025 with $81 million in cash and expects a slight increase in burn rate in 2026 due to intensified clinical and operating activities.

• Capital is sufficient to achieve 2026 objectives, including IDE trials and expanded R&D.

Market landscape and competitive differentiation

• nsPFA offers a non-thermal, highly efficient ablation method, delivering energy in billionths of a second, enabling broader and faster ablation compared to first-generation microsecond PFA.

• Proprietary technology and patents position the company as the sole participant in the nsPFA category, differentiating from open-source first-generation PFA competitors.